ArticleFrontiers in oncology2025
Gastric plexiform fibromyxoma: a case report and literature review.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Plexiform fibromyxoma (PF) is a rare mesenchymal tumour that primarily occurs in the stomach, with the antrum and pyloric region being the most common sites. A few cases have also been reported in the duodenum, jejunum, mediastinum, gallbladder, and other locations. Over 100 cases have been reported in the literature, with more than 30 cases reported in our country. A rare case of PF occurring in the cardia and fundus of the stomach is reported in this study. The tumour tissue showed a multinodular, plexiform growth pattern between the muscle bundles of the gastric wall, in which a myxoid matrix and thin-walled vessels were visible. The tumour cells were spindle shaped or short spindle shaped, with a mild change in morphological appearance, and mitotic figures were rare. The tumour cells showed immunohistochemical expression of vimentin and SMA, with focal expression of calponin and CD10. The Ki-67 proliferation index was approximately 5%. The plexiform fibromyxoma was characterized by benign biological behaviour, with surgical excision as the primary therapy. The patient was followed up for about 2 years after surgery without any tumour recurrence or metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.